3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
7
Lymphoma, B-Cell, Marginal Zone
4
Barrett Esophagus
4
Lymphoma, Large B-Cell, Diffuse
3
Breast Neoplasms
3
Zollinger-Ellison Syndrome
2
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma
2
Inflammation
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Ulcer
1
Solid Tumours
1
Solid Tumor
1
Prostate Cancer Patients
1
Precancerous Gastric Lesions
1
Pharmacokinetics of MDV3100
1
Peripheral Nervous System Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hyperuricemia
1
Healthy Adult Participants
1
Gout
1
Gastrinoma
1
Interventions
vandetanib
9
Everolimus
4
Sorafenib
3
sargramostim
2
cabozantinib
2
Trastuzumab
2
Sunitinib
2
Gefitinib
2
Doxorubicin
2
yeast-CEA vaccine
1
vatalanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
temsirolimus
1
tanespimycin
1
sacubitril and valsartan sodium hydrate drug combination
1
pralsetinib
1
pembrolizumab
1
pazopanib
1
pasireotide
1
nintedanib
1
motesanib diphosphate
1
mercaptoundecahydrododecaborate
1
lenvatinib
1
fluorodopa F 18
1
cixutumumab
1
anlotinib
1
aldesleukin
1
Vorinostat
1
Vinorelbine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Medullary
×
Omeprazole
×
Clear all
NCT01539655
2017-05-02
Vandetanib
Sanofi
Phase 1
Completed
34 enrolled